A Live Attenuated H7N3 Influenza Virus Vaccine is Well-tolerated and Immunogenic in a Phase I Trial in Healthy Adults

BACKGROUND: Live attenuated influenza vaccines (LAIV) are being developed and tested against a variety of influenza viruses with pandemic potential. We describe the results of an open label Phase I trial of a live attenuated H7N3 virus vaccine. METHODS AND FINDINGS: The H7N3 BC 2004/AA ca virus is a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Talaat, Kawsar R., Karron, Ruth A., Callahan, Karen A., Luke, Catherine J., DiLorenzo, Susan C., Chen, Grace L., Lamirande, Elaine W., Jin, Hong, Coelingh, Kathy L., Murphy, Brian R., Kemble, George, Subbarao, Kanta
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2771405/
https://ncbi.nlm.nih.gov/pubmed/19464558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2009.03.082
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars